• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths

FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths

May 20, 2022 By Sean Whooley

PhilipsThe FDA updated its communications on Philips‘ (NYSE:PHG) major ventilator recall with new data on device reports and patient deaths.

In June 2021, Philips Respironics recalled millions of certain ventilators, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) machines due to potential health risks caused by polyester-based polyurethane (PE-PUR) sound abatement foam breaking down. Foam particles could enter a device’s air pathway, causing a range of potential health problems and toxic, carcinogenic effects for the user.

According to the FDA’s notice, the agency received more than 21,000 medical device reports (MDRs), including 124 reports of death, associated with the PE-PUR foam breakdown or suspected foam breakdown in Philips Respironics’ ventilator devices between April 2021 and April 30, 2022.

Within the MDRs received by FDA — both mandatory reports from Philips and voluntary reports from healthcare professionals, consumers and patients — a range of injuries were reported, including cancer, pneumonia, asthma, other respiratory problems, infection, headache, cough, dyspnea (difficulty breathing), dizziness, nodules, and chest pain.

Philips submitted 30 MDRs between 2011 and April 2021 that they identified as associated with the PE-PUR foam breakdown. Eight of the reports were from the U.S., and there were no reports of patient injury or death within them.

Philips submitted 30 MDRs between 2011-April 2021 that they identified as associated with the PE-PUR foam breakdown. Eight of those reports were from the U.S. There were no reports of patient injury or death among those 30 MDRs. The FDA acknowledged the shortcomings of its MDR surveillance system, saying that they only comprise one of its important postmarket surveillance data sources

The FDA said the MDR system is limited in its effectiveness because the incidence, prevalence or cause of an event can’t typically be determined from the reporting system alone due to the under-reporting of events, inaccuracies in reports, lack of verification that the device caused the reported event and lack of information about the frequency of device use.

Amsterdam-based Philips said last year that it was no longer taking orders of sleep therapy systems as it dealt with the Class I recall, which saw it fall out of sleep therapy market for at least a year. In March, the FDA issued a notification order alerting Philips that its notification efforts on the recall of its ventilators have been inadequate to date.

Last month, the company revealed a Department of Justice subpoena for information related to the recall of its respiratory devices. The subpoena sought “information related to events leading to the Respironics recall.” Phillips said its subsidiaries are cooperating with investigators.

In an update issued on May 2, the FDA’s Center for Devices and Radiological Health (CDRH) proposed an order for Philips to submit a plan for the repair, replacement or refund of the purchase price of the recalled devices manufactured after November 2015.

When the FDA proposed its order to Philips earlier this month, a Philips spokesperson issued the following statement:

“We have been informed by the FDA that they are proposing to issue an order under section 518(b) of the Federal Food, Drug, and Cosmetic Act, in connection with the Philips Respironics recall for certain CPAP, BiPAP and mechanical ventilators. Philips is studying the information and intends to share its views with the FDA. We have been and continue to cooperate with the FDA.

“To date, Philips Respironics has produced a total of 1.1 million replacement devices and repair kits for customers and patients in the U.S., and aims to complete the vast majority of the repair and replacement program in 2022.”

A Philips spokesperson told MassDevice via email today that, since June 2021, Philips Respironics has worked with certified testing laboratories and other qualified third-party experts on a comprehensive test and research program on the PE-PUR foam to assess and scope potential health risks related to possible emission of particles.

In December, Philips’ update on the volatile organic compounds (VOC) test results demonstrated that exposure to level of VOCs identified for the first-generation DreamStation devices (that were not exposed to ozone cleaning) “is not typically anticipated to result in long-term health consequences for patients.”

Testing remains ongoing, along with analyses related to the affected CPAP and BiPAP devices, and the company expects to provide an update in the second quarter of 2022, the spokesperson said.

Additionally, initial testing suggests that PE-PUR foam degradation in CPAP devices is accelerated by repeated exposure to ozone cleaning, as the FDA and Philips have communicated that ozone is not an approved cleaning agent.

An analysis published in the American Journal of Respiratory and Critical Care Medicine (independent of Philips Respironics) did not find a higher risk of incident cancer among obstructive sleep apnea patients who used a Philips Respironics PAP device compared to those who used a PAP device from other manufacturers or who went without treatment.

 

This story was updated with additional information from Philips.

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Recalls, Regulatory/Compliance, Respiratory Tagged With: Philips, Philips Respironics, Royal Philips

In case you missed it

  • They said it at DeviceTalks Boston
  • Elucid raises $27M for heart disease diagnosis software
  • Summer health technology program brings diverse group of interns to Silicon Valley
  • BioSig expects to raise $3.5M from public offering
  • Haemonetics completes move to new Pennsylvania manufacturing facility
  • Vivera adds two industry veterans to its technology advisory board
  • Abbott Fund grants $750k to education, health equity program
  • Another Medtronic HVAD recall is serious
  • Endologix reports positive results from percutaneous bypass trial
  • NorthStar Medical names new president and chief operating officer
  • Vektor Medical names Rob Krummen as CEO
  • Baxter’s Volara lung therapy system recall is Class I
  • BD voluntarily recalls intraosseous products
  • Bioventus restructures $315M CartiHeal acquisition
  • Intrommune extends scope of Phase 1 trial for peanut-allergy-treating toothpaste
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
  • Hamilton Medical warns on some ventilators

RSS From Medical Design & Outsourcing

  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]
  • How SeaStar’s device calms hyperinflammation — and could prevent lasting damage from COVID cytokine storms
    SeaStar Medical recently won FDA breakthrough device designation for a new way to treat hyperinflammation with technology that could help fight chronic conditions from COVID-19 infections. The Denver-based medical developer is seeking a humanitarian device exemption for treating children with acute kidney injury (AKI) based on an FDA-funded study, SeaStar President and CEO Eric Schlorff… […]
  • How Avail Medsystems seeks to create a connected OR experience
    Much like a normal Starbucks-goer expects the coffee to taste a certain way at any location, Daniel Hawkins wants that type of experience in the operating room. Hawkins is the CEO of Avail Medsystems, a company developing telemedicine equipment that can connect surgeons, interventional specialists and medical device sales reps. Hawkins and the team at Avail… […]
  • How to leverage technology to drive diversity in clinical studies
    Convenience was the driver, and the traditional clinical trial model had to evolve when it came to a colorectal cancer screening study. The clinical study had 35,000 patients across the U.S. Chuanbo Xu, Freenome Cancer doesn’t discriminate. It’s the second-leading cause of death in the U.S. Early detection is key in treating — and even… […]
  • Medical device licensing pitfalls to avoid
    Prevent costly disputes caused by these common mistakes in patent license agreements. Marcelo Barros, Kathleen Daley, Brian Kacedon and Matthew Ritter, Finnegan Licensing and other technology transfer agreements can be critical for medical device companies that invest significantly into new technology R&D and seek and obtain intellectual property protection for those investments. But if these agreements… […]
  • Tolerance stack-up: Insight into the inner workings of high-density microelectronic medical devices
    Tolerance stack-up is a defining design concept to ensure new products are built efficiently and effectively.  Darren Gilmer, Intricon At a time when the future of micro-miniature medical devices seems unlimited, one fundamental reality remains firmly in place — the sizes and shapes of human anatomy. From blood vessels to ear canals, respiratory passages to… […]
  • Deburring and finishing for beautiful, functional medical devices
    The latest automated cutting tools help medical device manufacturers meet strict specs and high demand. Dave Sawicki, Xebec Increasing demand and advances in technology are driving growth in the medical device industry. Chronic diseases are more prevalent, and the aging population is larger, contributing to the demand for highly regulated Class III medical devices such… […]
  • FDA seeking innovations to move beyond heater-cooler device problems
    The FDA issued a notice today saying that it is working to evaluate new strategies to mitigate infections associated with heater-cooler devices. According to the notice, the administration is collaborating with professional societies, public health partners, heater-cooler manufacturers, and experts on the matter surrounding the heater-cooler devices used during medical and surgical procedures to warm… […]

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS